Want to see FR:ALERS full AI Analyst Report?
Eurobio-Scientific SA (ALERS) AI Stock Analysis
Top Page
Eurobio-Scientific SA
(Paris:ALERS)
The score is driven primarily by mixed financial performance—stronger solvency and continued positive cash generation, but materially weaker and more volatile profitability and cash conversion. Technicals add modest support as the stock trades above major moving averages, though momentum signals are not uniformly positive. Valuation is the main headwind due to the high P/E and lack of dividend yield support.
Eurobio-Scientific SA (ALERS) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 258.39M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,827
- Price to Earnings (P/E)
- 37.6
- Beta (1Y)
- 0.24
- Revenue Growth
- 6.28%
- EPS Growth
- 204.56%
- Country
- France
- Employees
- 443
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Eurobio-Scientific SA Business Overview & Revenue Model
Company Description
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The...
How the Company Makes Money
Eurobio Scientific makes money primarily by selling products and services used by laboratories for clinical testing and life-science research. Key revenue streams include: (1) Sales of in-vitro diagnostic products: revenue from commercializing IVD as...
Eurobio-Scientific SA Financial Statement Overview
Summary
Financials are mixed: the balance sheet is a clear positive (low leverage with debt-to-equity ~0.09 by 2025), and operating/free cash flow remain positive. However, profitability has structurally stepped down versus 2020–2022 with much thinner recent net margins (~2.9% in 2025) and weaker cash conversion (free cash flow roughly one-third of net income), limiting the overall financial score.
Income Statement
56NeutralBalance Sheet
74PositiveCash Flow
60Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 172.00M | 169.00M | 154.95M | 130.65M | 152.61M | 184.71M |
| Gross Profit | 75.43M | 68.40M | 71.95M | 57.49M | 65.04M | 97.44M |
| EBITDA | 35.13M | 32.39M | 29.05M | 24.55M | 40.20M | 79.63M |
| Net Income | 7.24M | 4.87M | 4.00M | 4.83M | 24.94M | 60.54M |
Balance Sheet | ||||||
| Total Assets | 427.08M | 256.76M | 257.17M | 316.33M | 330.42M | 209.22M |
| Cash, Cash Equivalents and Short-Term Investments | 26.34M | 20.66M | 23.07M | 89.03M | 85.94M | 102.39M |
| Total Debt | 14.74M | 16.02M | 34.05M | 100.66M | 113.60M | 15.68M |
| Total Liabilities | 239.12M | 72.83M | 78.31M | 141.16M | 157.75M | 49.00M |
| Stockholders Equity | 187.96M | 183.92M | 178.85M | 175.17M | 172.34M | 159.91M |
Cash Flow | ||||||
| Free Cash Flow | 5.05M | 6.28M | 13.45M | 22.71M | 39.01M | 63.61M |
| Operating Cash Flow | 19.67M | 18.85M | 16.70M | 26.77M | 41.85M | 65.46M |
| Investing Cash Flow | -164.23M | -12.89M | -10.74M | -318.00K | -141.76M | -5.47M |
| Financing Cash Flow | 143.04M | -8.16M | -72.09M | -23.50M | 82.31M | -23.75M |
Eurobio-Scientific SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Positive. The current price of 26.30 is above the 20-day moving average (MA) of 25.44, above the 50-day MA of 23.40, and above the 200-day MA of 22.62, indicating a bullish trend. The MACD of 0.67 indicates Positive momentum. The RSI at 80.47 is Negative, neither overbought nor oversold. The STOCH value of 89.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALERS.
Eurobio-Scientific SA Peers Comparison
Overall Rating
- FR:ALERS58Neutral
FR:ALIKO46Neutral
FR:ALMKT45Neutral
FR:ALNOV45Neutral
FR:ALMDT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:ALERS | 58Neutral | EUR 258.39M | 37.57 | 3.89% | ― | 6.28% | 204.56% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:ALIKO | 46Neutral | EUR 22.42M | -5.20 | -22.03% | ― | 37.28% | 7.83% |
| FR:ALMKT | 45Neutral | EUR 18.94M | 1.53 | -157.72% | ― | 3.38% | ― |
| FR:ALNOV | 45Neutral | EUR 31.94M | -0.76 | -159.70% | ― | 10.36% | 29.41% |
| FR:ALMDT | 43Neutral | EUR 180.85M | -3.00 | 271.64% | ― | 2.16% | -5.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALERS | Eurobio-Scientific SA | 26.30 | 2.15 | 8.90% | |
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.10 | -0.00 | -1.02% | |
| FR:ALNOV | Novacyt S.A. | 0.44 | -0.02 | -4.35% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.91 | -0.41 | -30.95% | |
| FR:ALIKO | Ikonisys SA | 1.42 | -0.04 | -2.74% | |
| FR:ALMDT | Median Technologies | 3.69 | 0.79 | 27.24% |
Eurobio-Scientific SA Corporate Events
EB Development moves toward full takeover and potential delisting of Eurobio Scientific
EB Development, the majority shareholder of Eurobio Scientific, plans to file a public buyout offer followed by a compulsory buyout at €25.30 per share, matching the price of its 2024 tender bid. The proposed offer implies significant premiums...
Eurobio Scientific lifts H1 revenue as proprietary and international sales drive strategic shift
Eurobio Scientific reported a 5% rise in first-half 2026 revenue to €84.5 million, with proprietary products growing 10% to €31.3 million and now accounting for 37% of sales, while international revenues reached 47%. Overall growth was la...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026